TLDR Patients with certain skin symptoms and high ANA titers should be monitored for potential systemic lupus.
The review discussed the pathogenesis, clinical presentation, diagnosis, and treatment of cutaneous lupus erythematosus (CLE), which can occur with or without systemic disease. CLE was categorized into chronic, subacute, and acute forms. The global prevalence of systemic lupus erythematosus (SLE) was 17-48 per 100,000 people, with skin disease being a common complaint in up to 70% of SLE patients. Common mucocutaneous manifestations included malar rash (40%), alopecia (24%), and oral ulcers (19%). High ANA titers (> 1:320) and arthralgias were identified as risk factors for the transition from cutaneous to systemic LE, indicating that patients with these symptoms should be closely monitored for potential development of SLE.
74 citations
,
March 2001 in “Seminars in Cutaneous Medicine and Surgery” The document concludes that skin biopsies, genetic and environmental factors, and specific treatments are important in managing cutaneous lupus erythematosus.
64 citations
,
May 2000 in “International Journal of Dermatology” Thalidomide improved lupus symptoms but caused nerve damage in some patients.
1 citations
,
January 2022 in “Advances in Dermatology and Allergology” Most patients with cutaneous lupus erythematosus in Bangladesh are young women, with chronic forms and photosensitivity being common.
November 2021 in “Chattagram Maa-O-Shishu Hospital Medical College Journal” Most patients with Cutaneous Lupus Erythematosus are young females, and dermatologists play a key role in diagnosis.
46 citations
,
January 2015 in “Pediatric Rheumatology” Skin symptoms are important for diagnosing and managing juvenile-onset systemic lupus erythematosus and usually get better with treatment.
149 citations
,
July 2002 in “Dermatologic clinics” Patients with certain skin symptoms and high ANA titers should be monitored for potential systemic lupus.
